does hims sell semaglutide & Hers stock falls 25% as FDA curtails compounded GLP-1s Hims & Hers launches Wegovy

L cells in the lower small intestine and colon excrete GIP, an incretin hormone, in response to fatty acids and glucose

Their GLP-1 and GIP-based therapies have demonstrated significant weight-loss outcomes while also showing potential benefits in managing several obesity-related conditions

Access is by referral to a tier 3 or specialist service, and supply has been limited

People who struggle with obesity or weight regain may experience several patterns: persistent hunger even after meals slow or stalled weight loss gradual regain of lost weight difficulty maintaining calorie restriction These patterns often reflect hormonal signals involved in appetite regulation